LIWANLI Innovation Co Ltd - Asset Resilience Ratio
LIWANLI Innovation Co Ltd (3054) has an Asset Resilience Ratio of 12.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LIWANLI Innovation Co Ltd (3054) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how LIWANLI Innovation Co Ltd's Asset Resilience Ratio has changed over time. See LIWANLI Innovation Co Ltd (3054) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down LIWANLI Innovation Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of LIWANLI Innovation Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$100.63 Million | 12.97% |
| Total Liquid Assets | NT$100.63 Million | 12.97% |
Asset Resilience Insights
- Moderate Liquidity: LIWANLI Innovation Co Ltd has 12.97% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
LIWANLI Innovation Co Ltd Industry Peers by Asset Resilience Ratio
Compare LIWANLI Innovation Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual Asset Resilience Ratio data for LIWANLI Innovation Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.30% | NT$89.50 Million ≈ $2.82 Million |
NT$792.19 Million ≈ $24.96 Million |
-1.86pp |
| 2023-12-31 | 13.16% | NT$109.75 Million ≈ $3.46 Million |
NT$834.17 Million ≈ $26.28 Million |
+2.07pp |
| 2022-12-31 | 11.09% | NT$89.35 Million ≈ $2.82 Million |
NT$805.93 Million ≈ $25.39 Million |
-20.02pp |
| 2021-12-31 | 31.11% | NT$294.88 Million ≈ $9.29 Million |
NT$947.90 Million ≈ $29.86 Million |
+18.46pp |
| 2020-12-31 | 12.65% | NT$126.93 Million ≈ $4.00 Million |
NT$1.00 Billion ≈ $31.61 Million |
-0.92pp |
| 2019-12-31 | 13.57% | NT$153.91 Million ≈ $4.85 Million |
NT$1.13 Billion ≈ $35.73 Million |
+1.48pp |
| 2018-12-31 | 12.10% | NT$128.45 Million ≈ $4.05 Million |
NT$1.06 Billion ≈ $33.45 Million |
+7.35pp |
| 2017-12-31 | 4.74% | NT$76.14 Million ≈ $2.40 Million |
NT$1.61 Billion ≈ $50.59 Million |
-15.43pp |
| 2016-12-31 | 20.17% | NT$350.08 Million ≈ $11.03 Million |
NT$1.74 Billion ≈ $54.68 Million |
+2.91pp |
| 2015-12-31 | 17.26% | NT$286.37 Million ≈ $9.02 Million |
NT$1.66 Billion ≈ $52.26 Million |
+3.08pp |
| 2014-12-31 | 14.18% | NT$271.65 Million ≈ $8.56 Million |
NT$1.92 Billion ≈ $60.37 Million |
+8.28pp |
| 2013-12-31 | 5.90% | NT$126.36 Million ≈ $3.98 Million |
NT$2.14 Billion ≈ $67.49 Million |
+0.24pp |
| 2012-12-31 | 5.66% | NT$83.87 Million ≈ $2.64 Million |
NT$1.48 Billion ≈ $46.70 Million |
-2.06pp |
| 2011-12-31 | 7.72% | NT$95.32 Million ≈ $3.00 Million |
NT$1.24 Billion ≈ $38.92 Million |
-26.50pp |
| 2009-12-31 | 34.21% | NT$422.14 Million ≈ $13.30 Million |
NT$1.23 Billion ≈ $38.88 Million |
+26.17pp |
| 2008-12-31 | 8.04% | NT$62.78 Million ≈ $1.98 Million |
NT$781.16 Million ≈ $24.61 Million |
+3.11pp |
| 2007-12-31 | 4.92% | NT$36.46 Million ≈ $1.15 Million |
NT$740.41 Million ≈ $23.33 Million |
+4.47pp |
| 2005-12-31 | 0.45% | NT$2.41 Million ≈ $75.90K |
NT$533.37 Million ≈ $16.80 Million |
-4.63pp |
| 2004-12-31 | 5.08% | NT$48.95 Million ≈ $1.54 Million |
NT$963.72 Million ≈ $30.36 Million |
-8.87pp |
| 2003-12-31 | 13.95% | NT$174.46 Million ≈ $5.50 Million |
NT$1.25 Billion ≈ $39.41 Million |
-- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more